Free Trial

Biofrontera (BFRI) Competitors

Biofrontera logo
$1.10 -0.03 (-2.65%)
Closing price 10/24/2025 03:59 PM Eastern
Extended Trading
$1.12 +0.01 (+1.36%)
As of 10/24/2025 05:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BFRI vs. OKUR, LVTX, XLO, ELUT, RVPH, BTAI, NEUP, MURA, BCAB, and ITRM

Should you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include OnKure Therapeutics (OKUR), LAVA Therapeutics (LVTX), Xilio Therapeutics (XLO), Elutia (ELUT), Reviva Pharmaceuticals (RVPH), BioXcel Therapeutics (BTAI), Neuphoria Therapeutics (NEUP), Mural Oncology (MURA), BioAtla (BCAB), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry.

Biofrontera vs. Its Competitors

Biofrontera (NASDAQ:BFRI) and OnKure Therapeutics (NASDAQ:OKUR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

In the previous week, Biofrontera had 3 more articles in the media than OnKure Therapeutics. MarketBeat recorded 4 mentions for Biofrontera and 1 mentions for OnKure Therapeutics. OnKure Therapeutics' average media sentiment score of 1.91 beat Biofrontera's score of 1.29 indicating that OnKure Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Biofrontera Positive
OnKure Therapeutics Very Positive

Biofrontera presently has a consensus price target of $2.75, suggesting a potential upside of 150.00%. OnKure Therapeutics has a consensus price target of $32.33, suggesting a potential upside of 873.90%. Given OnKure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe OnKure Therapeutics is more favorable than Biofrontera.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biofrontera
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
OnKure Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71

Biofrontera has higher revenue and earnings than OnKure Therapeutics. OnKure Therapeutics is trading at a lower price-to-earnings ratio than Biofrontera, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$37.32M0.30-$17.76M-$2.26-0.49
OnKure TherapeuticsN/AN/A-$52.67M-$4.80-0.69

OnKure Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -42.34%. OnKure Therapeutics' return on equity of -60.52% beat Biofrontera's return on equity.

Company Net Margins Return on Equity Return on Assets
Biofrontera-42.34% -1,104.09% -82.28%
OnKure Therapeutics N/A -60.52%-55.43%

Biofrontera has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, OnKure Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 91.0% of OnKure Therapeutics shares are held by institutional investors. 4.8% of Biofrontera shares are held by company insiders. Comparatively, 2.3% of OnKure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

OnKure Therapeutics beats Biofrontera on 9 of the 16 factors compared between the two stocks.

Get Biofrontera News Delivered to You Automatically

Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BFRI vs. The Competition

MetricBiofronteraMED IndustryMedical SectorNASDAQ Exchange
Market Cap$11.15M$3.46B$6.22B$10.81B
Dividend YieldN/A2.28%5.72%4.81%
P/E Ratio-0.4928.5131.5430.95
Price / Sales0.30497.40595.06133.74
Price / CashN/A46.9537.2561.86
Price / Book1.9310.4012.056.61
Net Income-$17.76M-$52.83M$3.34B$277.10M
7 Day Performance14.58%2.10%1.93%2.57%
1 Month Performance14.57%12.33%7.77%3.79%
1 Year Performance21.20%14.14%56.40%33.01%

Biofrontera Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BFRI
Biofrontera
2.4387 of 5 stars
$1.10
-2.7%
$2.75
+150.0%
+13.4%$11.15M$37.32M-0.4970News Coverage
High Trading Volume
OKUR
OnKure Therapeutics
3.9435 of 5 stars
$3.00
+2.4%
$32.33
+977.8%
-80.7%$39.64MN/A-0.63N/APositive News
Analyst Forecast
LVTX
LAVA Therapeutics
1.6707 of 5 stars
$1.47
-1.3%
$2.69
+82.7%
-19.5%$39.19M$11.98M-1.4060Analyst Forecast
High Trading Volume
XLO
Xilio Therapeutics
1.9996 of 5 stars
$0.76
+0.2%
$3.00
+297.1%
-14.7%$39.06M$6.34M-0.9970Analyst Forecast
ELUT
Elutia
2.9191 of 5 stars
$0.90
-0.2%
$7.00
+681.3%
-72.1%$38.05M$24.38M-0.85180News Coverage
Analyst Forecast
Gap Down
RVPH
Reviva Pharmaceuticals
3.6725 of 5 stars
$0.52
-2.9%
$4.86
+834.1%
-40.8%$37.12MN/A-0.805Positive News
Analyst Forecast
Options Volume
Gap Up
BTAI
BioXcel Therapeutics
3.9718 of 5 stars
$2.20
-3.9%
$39.75
+1,706.8%
-75.7%$36.66M$2.27M-0.1790News Coverage
Analyst Forecast
NEUP
Neuphoria Therapeutics
3.33 of 5 stars
$4.85
-68.5%
$28.00
+477.3%
N/A$36.31M$15.65M0.00N/ANews Coverage
Analyst Forecast
Insider Trade
Gap Up
High Trading Volume
MURA
Mural Oncology
2.8165 of 5 stars
$2.09
flat
$12.00
+474.2%
-40.1%$36.21MN/A-0.24119News Coverage
BCAB
BioAtla
0.798 of 5 stars
$0.69
+12.4%
N/A-60.2%$36.06M$11M-0.6360News Coverage
ITRM
Iterum Therapeutics
2.8294 of 5 stars
$0.73
-2.1%
$9.00
+1,126.3%
-40.6%$36.04MN/A-0.8610Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:BFRI) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners